The recent literature on spasmodic dysphonia is reviewed with regard to pathogenesis, differential diagnosis, treatment options, audits, and current methods of management.
INTRODUCTION
The focus of this review is spasmodic dysphonia, also called laryngeal dystonia. It will address differential diagnosis, methods of investigation, treatment, and management of this vocal cord function disorder in adults. It will not consider other laryngeal impairments such as paradoxical vocal fold motion disorder, difficulties pertaining to oromandibular or palatal function, or pulmonary conditions. Genetic aspects of spasmodic dysphonia will be considered, but not research dealing with the genetics of dystonia more generally. We review treatment options including surgery, neuromodulation, and intralaryngeal botulinum toxin type A (BoNT-A) injections; however, investigations regarding the pharmacological activity of other varieties are not included. Research published in languages other than English has been regrettably omitted.
BACKGROUND
Laryngoscopic visualization of abnormal spasms of the adductor muscles of the vocal cords during speaking was first described 150 years ago [1] . Years of speculation followed about whether these vocal symptoms were of organic or psychogenic origin. The abnormal vocal cord movements were characterized as dystonic tic in the 1980s [2] . Now, spasmodic dysphonia is recognized as an idiopathic focal dystonia affecting the intrinsic muscles of the larynx. It is classified as a rare disease by the National Institutes of Health, USA, with a prevalence of 14/ 100 000 predominantly affecting women (2.5 : 1). Peak onset incidence ages are ]. Traditionally, spasmodic dysphonia was thought to result from basal ganglia abnormalities. The pathogenesis of spasmodic dysphonia is currently considered to involve genetic and environmental factors [6] . Advances in imaging techniques using MRI, functional MRI, PET, transcranial magnetic stimulation, and transcranial sonography have enhanced our understanding of voice and speech production processes and the relationship between brain and laryngeal function.
Bilaterally distributed functional sensorimotor brain networks are imaged on MRI during oral sentence production speech in healthy controls [7 & ]. Speech production preferentially recruited in the inferior parietal lobule and cerebellum into large-scale networks. Interregional connectivity during speaking was stronger in the left hemisphere. [11, 12] , transcranial sonography [13] , and proprioceptive acuity [14] . The consensus points to the involvement of large-scale brain networks for speech production, and thus spasmodic dysphonia may be a heterogeneous disorder. Brain abnormalities appear to alter central control of voluntary voice production. Spasmodic dysphonia is likely because of a sensory disorder with the muscle spindle playing a central role [13] . The terms used to describe vocal movement impairments are not systematic or standardized. Nomenclature for vocal fold movement impairments, which currently apply to paresis or paralysis, could be expanded to include other movement variables, such as spasm [15 & ].
DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS
Although spasmodic dysphonia is most common, other dystonic laryngeal manifestations can exist: stridor, discoordinated breathing, paroxysmal cough, hiccups, and sneezing [4]. Focal dystonias have been recently described to selectively impair the cricothyroid [16] and hyoid muscle [17] . There are new descriptions of task-specific laryngeal spasms during singing, but not speaking [18 & ] and in dystonic cough [4] . ADSD and ABSD differ in their acoustic characteristics. In ADSD, hyperactivity of the adductor muscles (thyroarytenoid) results in voice breaks and consequent alterations in phonation and pitch. In ABSD, the spasms occur in the posterior cricoarytenoid muscles resulting in breathy, segmented speech. Patients with ADSD have greater difficulty with voiced sounds and ABSD with unvoiced sounds [19 & ]. Mixed spasmodic dysphonia involves characteristics of both. Perceptual voice features characteristic of ADSD and ABSD are similar. Both show slow, effortful, dysfluent speech, whereas whispering and nonspeech vocalization, crying, and laughing are normal [19 & ]. High subglottic pressure is associated with sudden adduction followed by high airflow associated with voice breaks. These prominent aerodynamic findings correlate with the perceptual judgements of ADSD [5 & ]. Accurate diagnosis of ADSD is challenging. The perceptual voice characteristics are often misdiagnosed as a functional voice disorder, muscle tension dysphonia. Owing to differences in their cause, treatment options are different. People with muscle tension dysphonia respond to traditional behavioural voice therapy unlike people with ADSD. Misdiagnosis can lead to ineffective, time-consuming, and expensive treatments. ADSD is typically diagnosed on clinical evaluation, and confirmed by videolaryngoscopic evidence of excessive spasmodic adduction of the vocal cords [20 & ,21] . In spasmodic dysphonia with dysphagia, videofluoroscopic swallowing investigation is used [22] . Voice spectography provides objective measures of sound alterations [20 & ]. Voice onset time in word initial voiceless consonant is found to differ between ADSD, ABSD, and controls, and may serve to further
KEY POINTS
Brain abnormalities in patients with spasmodic dysphonia may alter central control of voluntary voice production.
Spasmodic dysphonia may be because of a sensory disorder, with the muscle spindle playing a central role.
Diagnosis, treatment, and management need to be multifactorial and provided by an expert multidisciplinary team.
Differential diagnosis can be assisted by new acoustic and perceptual assessment tools.
Spasmodic dysphonia has a significant impact on QOL and leads to social penalty.
quantify spasmodic dysphonia voice symptoms [23] . ], and is useful for evaluating clinical effectiveness. Inclusion of wellness and/or QOL as an outcome measure is important to establish an evidence base for appropriate patient interventions. The experience of anxiety and situational voice problems can be assessed using the standardized selfreport Behaviour Assessment Battery modified for voice to quantify speech-related anxiety and negative speech-associated attitudes [27 & ]. Such a battery may help with diagnosis and designing a tailored multidimensional treatment plan for patients with spasmodic dysphonia [28] .
ASSESSMENT, TREATMENT, AND OUTCOME
Patients with ADSD and ABSD often complain that speaking is effortful. Vocal effort can be measured in a variety of ways: physical/physiological, aerodynamic, acoustic, and perceptual. A new measure -the Borg-CR10 -assesses the experience of vocal effort in voice-disordered patients but is not sensitive to measure the severity of impairment [29 & ]. The perception of vocal effort notably appears to be a trained phenomenon requiring an awareness of the internal sense of effort. Training for perception of effort and control for individual differences in internal awareness may be necessary to obtain valid effort ratings. In healthy individuals, an increased sense of vocal effort is reflected in measures of subglottal pressure, translaryngeal airflow, and maximum flow declination rate. The acoustic cepstral signal is positively correlated with vocal effort [30] . There is a stronger relationship between aerodynamic and acoustic measures of vocal effort within rather than across individuals [31] . Future work is needed to establish the relationship between these measures in voice-disordered individuals.
A qualitative study [32 && ] of expert and everyday listeners' perception of ADSD individuals demonstrated that both could appreciate the abnormal vocal quality. Both groups made assumptions about speakers with ADSD based on their voice and described the overall severity for ADSD speech as strongly related to perceived vocal effort. This study highlights the sound and speech characteristics of spasmodic dysphonia that evokes negative and judgemental reactions from listeners. As a result, individuals with spasmodic dysphonia experience a social penalty [33] . This emphasizes the need for a better understanding of the underlying basis of perceptual judgements of voice in everyday communication [32 && ]. Spasmodic dysphonia also impacts on individuals' QOL and productivity in the workplace. New standardized work-related QOL assessment scales are needed to determine how spasmodic dysphonia affects the quality and quantity of their work [34] .
Treatment for spasmodic dysphonia includes alcohol [35] , surgery [10, 36, 37] , neuromodulation [38 & ], and intralaryngeal injections of BoNT-A with various injection techniques using electromyography guidance [16, 39, 40] . Dosages and titrations of BoNT-A are also being investigated [41] [42] [43] [44] . Several audits of long-term outcomes have been carried out. The largest longitudinal group study on 1300 patients with spasmodic dysphonia (82% ADSD) has been updated [45 && ]. Retrospective demographic data are also reported from Mayo Clinic, Arizona, USA [46] and Mumbai, India [47] . In the Indian study, 80% of patients were men in contrast to international studies of spasmodic dysphonia, where the ratio is 80% women. Higher dose titrations were also used for both ADSD and ABSD compared with other centres.
CURRENT SITUATION
Time from onset to diagnosis can be an indicator of the quality of care received during the diagnosis of adult-onset dystonia [48 & ]. Although spasmodic dysphonia diagnosis has improved, it remains unacceptably delayed [49 && ]. Better education in the understanding of the particular signs and symptoms of this voice disorder is required. One limiting factor in arriving at a diagnosis, and a contributing factor to limited therapeutic interventions, is our lack of full understanding of spasmodic dysphonia phenomenology, cause, and pathophysiology [35] . Misdiagnosis can lead to ineffective time-consuming and expensive treatments that may not be beneficial. Moreover, there is no available gold standard test for differential diagnosis [50] . A large proportion of the spasmodic dysphonia population may be undiagnosed and untreated in the United
BoNT-A injections are less beneficial for some forms of spasmodic dysphonia. It is estimated that 90% of ADSD patients receive 90% benefit, whereas only 10% of ABSD patients receive 70% benefit. Cooccurring vocal tremor has an unpredictable response [35] . However, BoNT-A injections are expensive and typically must be repeated every 3-4 months throughout a patient's life, which may lead to both psychological and financial burden [35] . There is a complex relationship between the impact of diagnosis, clinical practice, prescription habits, health insurance rules, and patient compliance. In many countries, health insurance rules determine the maximum amount of intervention or cost, which significantly impacts on temporal variables of voice therapy. International consensus is required regarding duration and frequency, and optimal treatment practice [51] . With regard to QOL, patients with spasmodic dysphonia reported a negative impact on the quantity and quality of their work [34] . The timing of BoNT-A injections may play an important role in determining the degree to which the symptoms of spasmodic dysphonia affect a person's job performance.
Spasmodic dysphonia is now classified as a rare disease by the National Institute of Health, USA. At an international level, it is a category in the 'Rare Clinical Disease Network,' a part of the dystonia coalition working to advance the pace of clinical and translational research to find better treatments and a cure. The Strategy for Rare Diseases, National Health Service England's statement of intent, sets out 51 commitments agreed to be achieved by 2020, including: empowering those with rare disease, identifying and preventing rare disease, diagnosis and early intervention, coordination of care, and role of research [52] .
CONCLUSION
Spasmodic dysphonia is a heterogeneous, multifaceted, and multifactorial chronic and incurable voice disorder of unknown cause. It is still under or misdiagnosed. There is no gold standard diagnostic test for differential diagnosis. Accurate diagnosis and treatment require a multidisciplinary team of experts. Current treatment options offer symptomatic relief. Intralaryngeal, electromyographyguided injections of BoNT-A are still the current gold standard treatment modality. On the plus side, advances in imaging techniques have improved the understanding of the neurogenic basis for the disorder. Spasmodic dysphonia is now classified as a rare disease in the United States. We urgently hope that this recognition can be adopted by other countries to facilitate the empowerment of individuals with spasmodic dysphonia and develop international standards for diagnosis, treatment, and care.
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